RHY 4.11% 7.0¢ rhythm biosciences limited

Ann: Rhythm Maintains Ongoing ISO13485 Certification, page-22

  1. 116 Posts.
    lightbulb Created with Sketch. 25
    RHY Announcement extract - April 2, 2020

    “Despite the current macroeconomic climate, I would remind all stakeholders that in addition
    to potentially replacing or working as an adjunct< of the current faecal testing, the ColoSTAT®
    test kit will enable the reading of cancerous samples, rather than just the presence of blood
    in faeces. More so, we believe a simple blood test should improve the current poor compliance
    record of the faecal immunochemical test (FIT), saving lives and healthcare costs globally,”
    said Mr Gilbert.
    “We strongly believe ColoSTAT® has a global market, whereby the ColoSTAT® test could be
    added to the standard panel of blood tests a GP may run for their patients as part of their
    annual check-up. Further, once approved, ColoSTAT® has the potential to attract
    reimbursement by both governments and health insurance companies worldwide” Mr Gilbert
    said.


    Last edited by penniem: 16/02/22
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.